Schering to globalize clinical trial management
Executive Summary
Schering-Plough plans to globalize its clinical trial operations as part of its action agenda initiated in 2003 which seeks to transform the company into a high-performance competitor. Schering expects its Global Clinical Harmonization program will ensure better planning, prioritization, consistency and, as a result, improve efficiencies. One change will see the integration of Phase IV studies under the same roof as earlier development areas. Schering announced that it entered the "turnaround" phase of its action agenda late last year (1"The Pink Sheet" Nov. 7, 2005, p. 18). The globalization of clinical trial activities is not expected to result in head-count reductions...
You may also be interested in...
Schering Seeks Salvation In External Deals; Hassan Outlines Licensing Plan
The solution to the "innovation threat" facing big pharma lies in making deals outside the company, Schering-Plough CEO Fred Hassan said during an R&D update Nov. 1
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.